Tag: HEA MTC PHA BIO

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug...

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

Halozyme to Report Second Quarter 2025 Financial and Operating Results

SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and...

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...

DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda

The Conference Forum announces the 15th annual PODD Drug Delivery Conference's 2025 agenda and featured sessions. NEW YORK, July 16, 2025 /PRNewswire/ -- Today, PODD: Partnership...

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Alkermes to Report Second Quarter Financial Results on July 29, 2025

DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m....

PHREESIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

Attorney John Gomez Announces Whistleblower Retaliation Lawsuit on Behalf of Former Albert Einstein Academies Principal

BABCOCK & WILCOX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors to Secure Counsel Before Important June 15 Deadline in...

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

Alkermes to Report Second Quarter Financial Results on July 29, 2025

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us